India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Amifampridine Tablets, 10 mg.
Amifampridine Tablets, 10 mg, are bioequivalent to the reference listed drug, Firdapse Tablets, 10 mg, from Catalyst Pharmaceuticals Inc, for the indication in the approved labeling. Firdapse Tablets are indicated for people aged 6 years and older living with Lambert-Eaton myasthenic syndrome (LEMS), to help maintain muscle strength and mobility.
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity.
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
United Therapeutics receives FDA clearance to advance inhaled PAH therapy into clinical trials
US WorldMeds acquires Orbus Therapeutics
Enhertu wins EU approval for HER2-positive early breast cancer treatment
Citius Oncology reports growth in LYMPHIR unit shipments to US wholesalers
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Lynch Regenerative Medicine's Phase IIb clinical trial of rhPDGF-BB injection cleared by FDA
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
GSK wins US FDA approval for chronic hepatitis B treatment Hibsago
Solventum's combined use of Restrata Matrix and Solventum VAC Therapy receives FDA 510(k) clearance